CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures., PMID:40435316
CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures., PMID:40435316
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB., PMID:40251684
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB., PMID:40251684
A proteogenomic tool uncovers protein markers for human microglial states., PMID:40236015
A proteogenomic tool uncovers protein markers for human microglial states., PMID:40236015
Secretion of GPNMB from Neural Stem Cells Induced by ET-1 Contributes to Angiogenesis after Spinal Cord Injury., PMID:39327246
Secretion of GPNMB from Neural Stem Cells Induced by ET-1 Contributes to Angiogenesis after Spinal Cord Injury., PMID:39327246
An Inducible Luminescent System to Explore Parkinson's Disease-Associated Genes., PMID:39273438
An Inducible Luminescent System to Explore Parkinson's Disease-Associated Genes., PMID:39273438
A correctable immune niche for epithelial stem cell reprogramming and post-viral lung diseases., PMID:39052353
A correctable immune niche for epithelial stem cell reprogramming and post-viral lung diseases., PMID:39052353
Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma., PMID:38839271
Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma., PMID:38839271
Glycoprotein nonmetastatic melanoma protein B impacts the malignant potential of bladder cancer cells through its hem-immunoreceptor tyrosine-based activation motif., PMID:38501371
Glycoprotein nonmetastatic melanoma protein B impacts the malignant potential of bladder cancer cells through its hem-immunoreceptor tyrosine-based activation motif., PMID:38501371
Truncated GPNMB, a microglial transmembrane protein, serves as a scavenger receptor for oligomeric β-amyloid peptide1-42 in primary type 1 microglia., PMID:38361142
Truncated GPNMB, a microglial transmembrane protein, serves as a scavenger receptor for oligomeric β-amyloid peptide1-42 in primary type 1 microglia., PMID:38361142
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma., PMID:37095531
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma., PMID:37095531
Human Antibody VH Domains Targeting GPNMB and VCAM-1 as Candidate Therapeutics for Cancers., PMID:37067377
Human Antibody VH Domains Targeting GPNMB and VCAM-1 as Candidate Therapeutics for Cancers., PMID:37067377
[Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis]., PMID:36973196
[Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis]., PMID:36973196
ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer., PMID:36900378
ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer., PMID:36900378
Molecularly Imprinted Nanobeacons Redirect Innate Immune Killing towards Triple Negative Breast Cancer., PMID:36814079
Molecularly Imprinted Nanobeacons Redirect Innate Immune Killing towards Triple Negative Breast Cancer., PMID:36814079
Macrophage-derived GPNMB trapped by fibrotic extracellular matrix promotes pulmonary fibrosis., PMID:36732560
Macrophage-derived GPNMB trapped by fibrotic extracellular matrix promotes pulmonary fibrosis., PMID:36732560
TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma., PMID:35158847
TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma., PMID:35158847
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin., PMID:35110681
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin., PMID:35110681
Antiaging Vaccines Targeting Senescent Cells., PMID:35081729
Antiaging Vaccines Targeting Senescent Cells., PMID:35081729
[89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B-targeted Therapy in Triple-negative Breast Cancer., PMID:35027482
[89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B-targeted Therapy in Triple-negative Breast Cancer., PMID:35027482
Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression., PMID:34673297
Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression., PMID:34673297
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications., PMID:34656365
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications., PMID:34656365
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)., PMID:34590018
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)., PMID:34590018
Glycoprotein non-metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation., PMID:34327762
Glycoprotein non-metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation., PMID:34327762
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study., PMID:34016993
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study., PMID:34016993
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma., PMID:32823698
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma., PMID:32823698
DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors., PMID:31822499
DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors., PMID:31822499
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group., PMID:31586757
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group., PMID:31586757
Gpnmb secreted from liver promotes lipogenesis in white adipose tissue and aggravates obesity and insulin resistance., PMID:32694855
Gpnmb secreted from liver promotes lipogenesis in white adipose tissue and aggravates obesity and insulin resistance., PMID:32694855
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma., PMID:30690710
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma., PMID:30690710
111In-Labeled Glycoprotein Nonmetastatic b (GPNMB) Targeted Gemini Surfactant-Based Nanoparticles against Melanoma: In Vitro Characterization and in Vivo Evaluation in Melanoma Mouse Xenograft Model., PMID:30605337
111In-Labeled Glycoprotein Nonmetastatic b (GPNMB) Targeted Gemini Surfactant-Based Nanoparticles against Melanoma: In Vitro Characterization and in Vivo Evaluation in Melanoma Mouse Xenograft Model., PMID:30605337
Antibody-drug conjugates in triple negative breast cancer., PMID:30175620
Antibody-drug conjugates in triple negative breast cancer., PMID:30175620
Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients., PMID:30049749
Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients., PMID:30049749
Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma., PMID:29706186
Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma., PMID:29706186
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent., PMID:29262642
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent., PMID:29262642
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target., PMID:29097143
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target., PMID:29097143
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer., PMID:28546082
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer., PMID:28546082
GPNMB promotes proliferation of developing eosinophils., PMID:28104809
GPNMB promotes proliferation of developing eosinophils., PMID:28104809
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB., PMID:27515299
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB., PMID:27515299
Gpnmb/osteoactivin: an indicator and therapeutic target in tumor and nontumorous lesions., PMID:29441921
Gpnmb/osteoactivin: an indicator and therapeutic target in tumor and nontumorous lesions., PMID:29441921
Progress and opportunities for immune therapeutics in osteosarcoma., PMID:27605071
Progress and opportunities for immune therapeutics in osteosarcoma., PMID:27605071
The novel monoclonal antibody 9F5 reveals expression of a fragment of GPNMB/osteoactivin processed by furin-like protease(s) in a subpopulation of microglia in neonatal rat brain., PMID:27464357
The novel monoclonal antibody 9F5 reveals expression of a fragment of GPNMB/osteoactivin processed by furin-like protease(s) in a subpopulation of microglia in neonatal rat brain., PMID:27464357
Approach to the Triple Negative Breast Cancer in New Drugs Area., PMID:27252813
Approach to the Triple Negative Breast Cancer in New Drugs Area., PMID:27252813
Osteoactivin Promotes Migration of Oral Squamous Cell Carcinomas., PMID:26636434
Osteoactivin Promotes Migration of Oral Squamous Cell Carcinomas., PMID:26636434
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma., PMID:26305408
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma., PMID:26305408
Identification of Putative ORF5 Protein of Porcine Circovirus Type 2 and Functional Analysis of GFP-Fused ORF5 Protein., PMID:26035722
Identification of Putative ORF5 Protein of Porcine Circovirus Type 2 and Functional Analysis of GFP-Fused ORF5 Protein., PMID:26035722
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer., PMID:25847941
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer., PMID:25847941
Chondroitin Sulfate-E Binds to Both Osteoactivin and Integrin αVβ3 and Inhibits Osteoclast Differentiation., PMID:25820496
Chondroitin Sulfate-E Binds to Both Osteoactivin and Integrin αVβ3 and Inhibits Osteoclast Differentiation., PMID:25820496
The potential role of the glycoprotein osteoactivin/glycoprotein nonmetastatic melanoma protein B in pancreatic cancer., PMID:25426614
The potential role of the glycoprotein osteoactivin/glycoprotein nonmetastatic melanoma protein B in pancreatic cancer., PMID:25426614
Myeloid cells' evasion of melanoma immunity., PMID:25318429
Myeloid cells' evasion of melanoma immunity., PMID:25318429
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer., PMID:25267761
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer., PMID:25267761
For research use only. Not for human or drug use.
